U.S. markets open in 2 hours 9 minutes

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.19+0.01 (+0.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.18
Open11.12
Bid11.00 x 900
Ask0.00 x 1200
Day's Range10.88 - 11.33
52 Week Range8.80 - 31.38
Volume730,924
Avg. Volume746,561
Market Cap425.383M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-3.45
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020
    GlobeNewswire

    G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

    RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET. The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 6634419. The live and archived webcast will be available on the Events & Presentations page of the G1 website.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.Contact: Jeff Macdonald Senior Director, Investor Relations & Corporate Communications 919-907-1944 jmacdonald@g1therapeutics.com

  • GlobeNewswire

    G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)

    RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be featured at the North America Conference on Lung Cancer (NACLC) being held October 16-17. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. G1 abstract titles are below; more details are available on the International Association for the Study of Lung Cancer (IASLC) website. Title: Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression Oral Presentation/Abstract Number: OA03.08 Presenter: Renata Ferrarotto, University of Texas MD Anderson Cancer Center, Houston, TXTitle: Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age Poster Number: MO01.40 Authors: J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR, et alTitle: Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer Poster Number: MO01.41 Authors: Janakiraman Subramanian, Saint Luke’s Cancer Institute/University of Missouri, Kansas City, MO, et alTitle: Myelopreservation with trilaciclib regardless of risk of chemotherapy-induced febrile neutropenia and/or anemia/red blood cell transfusions Poster Number: MO01.42 Authors: Maen Hussein, Florida Cancer Specialists, Leesburg, FL, et alAbout Trilaciclib Trilaciclib is a first-in-class FDA-designated "Breakthrough Therapy" designed to improve outcomes for people with cancer who are treated with chemotherapy. Positive data have been reported from four randomized trials – three in small cell lung cancer (SCLC) and one in metastatic triple-negative breast cancer (mTNBC). The FDA accepted our New Drug Application (NDA) for trilaciclib for SCLC patients being treated with chemotherapy and granted Priority Review in August 2020 with a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2021. We plan to begin a Phase 3 trial in colorectal cancer in the fourth quarter of 2020. In addition, we have a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib in a randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL for neoadjuvant treatment of locally advanced breast cancer.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.Contact: Investors: Jeff Macdonald Senior Director, Investor Relations & Corporate Communications 919-907-1944 jmacdonald@g1therapeutics.comMedia: Christine Rogers G1 Therapeutics, Inc. Associate Director, Corporate Communications 984-365-2819 crogers@g1therapeutics.com

  • GlobeNewswire

    G1 Therapeutics Announces Chief Executive Officer Succession Plan

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that effective January 1, 2021, Mark Velleca, M.D. Ph.D., will transition to the role of senior advisor and continue to serve as a member of the G1 Board of Directors. John (“Jack”) Bailey, a member of the company’s board, has been named as G1’s next Chief Executive Officer.